BioSpace News Archive

Board-certified plastic surgeon Dr. Lawrence Iteld now offers BODYtite for tightening skin and reducing fat

Urovant Sciences (Nasdaq: UROV) (“Urovant”) announced today that its majority shareholder, Roivant Sciences Ltd. (“Roivant”), and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506) (“Sumitomo Dainippon Pharma”), a leading global Japanese pharmaceutical company, have completed their transaction that creates a significant, multinational Sumitomo Dainippon Pharma-Roivant Alliance

Urovant expects to borrow $87.5M under this facility of which approximately $48 million will be used to repay Urovant’s outstanding Hercules Capital loans in full.

Improved SpO2 Accuracy Now Available for All Patient Populations

The Company invited certain local VIP customers to attend the opening ceremony and marketing sales event on December 28, 2019.

Trial to assess safety and tolerability of mavorixafor in combination with ibrutinib in WM patients with MYD88/CXCR4 double mutation associated with treatment resistance

LIFE Extend and LIFE Fasting Tracker Have New Wearable Integrations, Partnerships, Marketplaces and More

Further Highlights the Case for Change at Enzo, Including its History of Failed Oversight and Significant Underperformance

Hologic, Inc. (Nasdaq: HOLX) announced today that it has completed the previously announced divestiture of its Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, less certain closing adjustments

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will participate in the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020.